Terms: = Bone cancer AND FGFR1OP, FOP, 11116, ENSG00000213066 AND Treatment
11 results:
1. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPfop).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract] [Full Text] [Related]
2. Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature.
Botman E; Netelenbos JC; Rustemeyer T; Schoonmade LJ; Nieuwenhuijzen JA; Teunissen BP; Visser M; Raijmakers P; Lammertsma AA; Dahele M; Eekhoff M
Front Endocrinol (Lausanne); 2020; 11():6. PubMed ID: 32117050
[TBL] [Abstract] [Full Text] [Related]
3. BMX activates Wnt/β-catenin signaling pathway to promote cell proliferation and migration in breast cancer.
Li K; Pan WT; Ma YB; Xu XL; Gao Y; He YQ; Wei L; Zhang JW
Breast Cancer; 2020 May; 27(3):363-371. PubMed ID: 31728872
[TBL] [Abstract] [Full Text] [Related]
4. Challenges in the treatment of fibrodysplasia ossificans progressiva.
Gencer-Atalay K; Ozturk EC; Yagci I; Ata P; Delil K; Ozgen Z; Akyuz G
Rheumatol Int; 2019 Mar; 39(3):569-576. PubMed ID: 30343406
[TBL] [Abstract] [Full Text] [Related]
5. Early clinical observations on the use of imatinib mesylate in fop: A report of seven cases.
Kaplan FS; Andolina JR; Adamson PC; Teachey DT; Finklestein JZ; Ebb DH; Whitehead B; Jacobs B; Siegel DM; Keen R; Hsiao E; Pignolo RJ
Bone; 2018 Apr; 109():276-280. PubMed ID: 28736245
[TBL] [Abstract] [Full Text] [Related]
6. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
Pacifici M; Shore EM
Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
[TBL] [Abstract] [Full Text] [Related]
7. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway.
Ma Y; Zhu B; Liu X; Yu H; Yong L; Liu X; Shao J; Liu Z
J Exp Clin Cancer Res; 2015 Oct; 34():115. PubMed ID: 26444270
[TBL] [Abstract] [Full Text] [Related]
9. Radiation therapy in treatment of fibrodysplasia ossificans progressiva: a case report and review of the literature.
Soldić Z; Murgić J; Radić J; Dabelić N; Jazvić M; Brozić JM; Kusić Z
Coll Antropol; 2011 Jun; 35(2):611-4. PubMed ID: 21755739
[TBL] [Abstract] [Full Text] [Related]
10. Secreted Frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling.
von Marschall Z; Fisher LW
Biochem Biophys Res Commun; 2010 Sep; 400(3):299-304. PubMed ID: 20723538
[TBL] [Abstract] [Full Text] [Related]
11. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva.
Kitterman JA; Kantanie S; Rocke DM; Kaplan FS
Pediatrics; 2005 Nov; 116(5):e654-61. PubMed ID: 16230464
[TBL] [Abstract] [Full Text] [Related]
